Dianthus Therapeutics, Inc.
DNTH
$85.74
-$0.41-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 63.03% | -28.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 63.03% | -28.28% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 63.03% | -28.28% | |||
| SG&A Expenses | 25.86% | 20.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.69% | 71.63% | |||
| Operating Income | 33.09% | -72.61% | |||
| Income Before Tax | 36.62% | -75.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.62% | -75.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.62% | -75.25% | |||
| EBIT | 33.09% | -72.61% | |||
| EBITDA | 33.11% | -72.66% | |||
| EPS Basic | 40.66% | -47.28% | |||
| Normalized Basic EPS | 40.37% | -40.14% | |||
| EPS Diluted | 40.66% | -47.28% | |||
| Normalized Diluted EPS | 40.37% | -40.14% | |||
| Average Basic Shares Outstanding | 6.81% | 18.99% | |||
| Average Diluted Shares Outstanding | 6.81% | 18.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||